{{'Search' | translate}}
 

Human recombinant IL-6

Company: D Systems
Catalog#: 206-IL/CF
Bio-protocol()
Company-protocol()
Other protocol()

Methodology for in vitro Assessment of Human T Cell Activation and Blockade
Author:
Date:
2020-06-05
[Abstract]  Methods to test both the functionality and mechanism of action for human recombinant proteins and antibodies in vitro have been limited by multiple factors. To test the functionality of a recombinant protein or antibody, the receptor, the receptor-associated ligand, or both must be expressed by the cells present within the in vitro culture. While the use of transfected cell lines can circumvent this gap, the use of transfected cell lines does not allow for studying the native signaling pathway(s) modulated by the specific recombinant protein or antibody in primary cells. The present protocol utilizes sort purified CD14+ monocytes and T cells, both CD4+ T cells and CD8+ T cells, from healthy donors in a co-culture system. This methodology ... [摘要]  [摘要 ] 在体外测试人重组蛋白和抗体的功能和作用机理的方法受到多种因素的限制。要测试重组蛋白或抗体的功能,是受体,受体相关配体或两者它必须由体外培养物中存在的细胞表达,尽管使用转染的细胞系可以规避这一差距,但使用转染的细胞系并不能研究由特定重组蛋白或重组蛋白调控的天然信号通路(S)。抗体原代细胞,本协议利用排序纯化的CD14 Tasu 单核细胞和T细胞,这两种CD4 Tasu T细胞和CD8 Tasu T细胞,从他ALTH Ÿ 的捐助方共培养体系。这种方法特别相关的测试重组镨大肠菌素或抗体,是用于治疗自身免疫性疾病和癌症的推定疗法。目前的研究方案着重于含有B7-H4表达蛋白的共培养物 上皮细胞加上自体CD4 + T细胞或CD8 + T细胞,可以根据用户的特定需求修改方案。

背景 ] 临床使用检查点抑制剂治疗的,例如,抗CTLA-4和抗PD-1,已被证明可用作癌症治疗以增强抗肿瘤的免疫应答(柯伦等人,2010; 顾彬等等人,2014年),尽管在一线治疗失败的患者中获得成功,但仅约20%的接受治疗的患者对检查点抑制剂抗体治疗产生了反应,这种对患者无效的治疗可能是多因素的,也可能反映了特定类型。患者向临床医生提出的癌症( Podojil等人,2020)。肿瘤细胞中存在的肿瘤细胞和单核细胞/巨噬细胞表达B7- ...

Comments